Table 1.
Characteristics and comparisons of patients with immature versus mature membranes
| Immature (15 eyes) | Mature (25 eyes) | P value | |
| Mean age in years (SD) | 81.80 (5.82) | 79.04 (8.81) | 0.288 |
| Female (proportion) | 7/15 (46.7%) | 14/25 (56.0%) | 0.745 |
| Treatment-naïve eyes (proportion) | 11/15 (73.3%) | 9/25 (36.0%) | 0.048† |
| Median number of IVI (IQR) | 0 (0–8) | 6 (0–18) | 0.042*† |
| Subgroup of treated eyes | 15 (11–43.5) | 17 (8.5–23) | 0.850 |
| IVI groups (injections, n) | |||
| 0 | 10 | 5 | |
| ≤20 | 3 | 9 | |
| >20 | 1 | 5 | |
| Overall | 0.035† | ||
| Mean IVI per month (SD) | 0.18 (0.36) | 0.33 (0.33) | 0.045† |
| Subgroup of treated eyes | 0.69 (0.39) | 0.52 (0.28) | 0.329 |
| Anti-VEGF type | |||
| Ranibizumab | 3 (20.0%) | 6 (24.0%) | |
| Aflibercept | 1 (6.7%) | 6 (24.0%) | |
| Both | 1 (6.7%) | 4 (16.0%) | |
| Overall | 0.875 | ||
| Mean disease duration in months (SD) | 13.39 (28.14) | 22.77 (26.41) | 0.061* |
| Mean BCVA in letters (SD) | 58.27 (17.19) | 44.48 (24.09) | 0.081* |
| Presence of IRF (proportion) | 3/15 (20.0%) | 4/25 (16.0%) | 0.747 |
| Presence of SRF (proportion) | 7/15 (46.7%) | 3/25 (12.0%) | 0.014† |
*Wilcoxon rank-sum (Mann-Whitney) test.
†Statistically significant
BCVA, best corrected visual acuity; IRF, intraretinal fluid; IVI, intravitreal injection; SRF, subretinal fluid; VEGF, vascular endothelial growth factor.